Evidence map›Paper›PMID 36825105›Full record

ArticleCase reports in oncology

BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report.

Vasu Munjapara, Thatcher Heumann, Karisa C Schreck, John M Gross, Carlos Perez-Heydrich, Sachin K Gujar, Charles G Eberhart, Matthias Holdhoff

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Systemic metastases in a BRAF V600E-mutant pleomorphic xanthoastrocytoma classified by DNA methylation: treatment with BRAF/MEK inhibitors and liquid biopsy monitoring.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  2. A Rare Case of Glioblastoma with Osseous Metastases.The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques · 2024
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Vasu MunjaparaaDepartment of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Thatcher HeumannaDepartment of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Karisa C SchreckaDepartment of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
John M GrosscDepartment of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Carlos Perez-HeydrichaDepartment of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Sachin K GujardDepartment of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Charles G EberhartcDepartment of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Matthias HoldhoffaDepartment of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Johns Hopkins University · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
NCI NIH HHS P30 CA006973
6 · The paper itself

Abstract

Recent advancements in understanding the biology of glioblastomas (GBM) and increasing adoption of genomic sequencing in oncology practice have led to the discovery of several targetable mutations in these cancers. Among them, the BRAF V600E mutation can be found in approximately 3% of GBM. Despite the aggressive nature of GBM, metastatic disease is rarely observed. While there are growing data utilizing BRAF-targeting strategies in patients with GBM, data examining their efficacy in cases of metastatic GBM are lacking. We present the case of a 46-year-old female with GBM, isocitrate dehydrogenase (IDH)-wildtype and O

Indexed as

Actionable mutationBRAF V600E-mutantGlioblastomaMetastaticTargeted therapy

Identifiers

PMID36825105
PMCPMC9941771
OpenAlexW4303470809

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.